{
  "docId": "019de075-7d9e-72c3-b72b-f46b67767727",
  "docSlug": "53c1bfc711678d7524a7d4316a5473e9",
  "documentTitle": "Chimerix | Investor Presentation Deck | 43 slides",
  "authorId": "chimerix",
  "authorName": "Chimerix",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 38,
  "pageCount": 43,
  "prevPage": 37,
  "nextPage": 39,
  "slideType": "solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a visual comparison of tumor burden in mice to demonstrate efficacy.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-7d9e-72c3-b72b-f46b67767727/38",
  "deckHref": "/decks/019de075-7d9e-72c3-b72b-f46b67767727",
  "deckJsonHref": "/decks/019de075-7d9e-72c3-b72b-f46b67767727.json",
  "deckAnchorHref": "/decks/019de075-7d9e-72c3-b72b-f46b67767727#slide-38",
  "components": [
    {
      "bbox": {
        "h": 0.33,
        "w": 0.25,
        "x": 0.626,
        "y": 0.38
      },
      "kind": "image",
      "text": "Vehicle, ONC201, ONC212 mouse tumor imaging",
      "attrs": null,
      "subkind": "photo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "babbe888-73ac-4d1b-9917-7c7e81521765",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.53,
        "x": 0.039,
        "y": 0.24
      },
      "kind": "list",
      "text": "Distinct molecular target (GPR132) and efficacy profile relative to ONC201/ONC206\nEfficacy in preclinical models of advanced cancers\nGLP-tox studies complete, potential to advance to IND\nPartnerships established for early-stage clinical trials with Brown University and MD Anderson Cancer Center\nPreclinical studies are ongoing to evaluate additional oncology indications and predictive biomarkers for ONC212 for clinical development",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d179288e-2e2f-4859-a994-0340b90328b1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.28,
        "x": 0.594,
        "y": 0.23
      },
      "kind": "paragraph",
      "text": "Pancreatic cancer model shows the potential of ONC212",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5caffff0-b8ec-442a-bb94-2afd73347689",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.015,
        "w": 0.108,
        "x": 0.105,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "1. Lev et al, Oncotarget 2017",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "908422bf-e511-4811-8d34-79dff873d22e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.035,
        "w": 0.386,
        "x": 0.307,
        "y": 0.068
      },
      "kind": "title",
      "text": "ONC212: GPR132 + ClpP Agonist",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7331dd51-28b2-4ad1-aa4f-be857b72f0a3",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 43,
      "from": 16,
      "beatId": "159a3ef0-298f-499a-afc1-676405bbdbe9",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The deck presents ONC201 as a solution, including its mechanism of action, market opportunity, and development plans",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 43,
      "from": 16,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "cb576a48-1f93-4d7c-8d9b-075787961712",
      "evidence": "The deck presents ONC201's potential for efficacy and market opportunity",
      "position": 1,
      "objective": "Can ONC201 be a quick win and a big bet for Chimerix?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.6,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}